Application of asarone in preparation of medicine for treating and / or preventing eye diseases, composition and application of composition
By using a combination of ingredients such as α-asarone to prepare eye drops, oral medications, or injections, the problem of the lack of effective treatment and prevention of eye diseases in the prior art has been solved, and effective prevention and treatment of glaucoma, optic neuritis, diabetic retinopathy, macular degeneration, cataracts, and dry eye syndrome have been achieved.
Patent Information
- Application Number
- CN202411061594.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-05
AI Technical Summary
Current technologies lack effective drug treatments and preventive methods for eye diseases such as glaucoma, optic neuritis, diabetic retinopathy, macular degeneration, cataracts, and dry eye syndrome, especially because these diseases have complex pathogenesis and existing treatments have problems such as large adverse reactions and poor treatment compliance.
An eye drop, oral, or injectable formulation is prepared by combining at least one of α-asarone, β-asarone, and γ-asarone with soybean oil, egg yolk lecithin, glycerin, and sodium hydroxide, for the treatment and prevention of the aforementioned eye diseases.
This composition can effectively reduce intraocular pressure, protect retinal ganglion cells, improve retinal function, reduce vascular leakage caused by neovascular age-related macular degeneration, reduce MDA content in retinal tissue of optic neuritis and cataracts, reduce retinal cell apoptosis in diabetic retinopathy, and increase tear secretion in rats with dry eye, thus providing an effective prevention and treatment for the above-mentioned diseases.
Smart Images

Figure CN118924710A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to the use of alpha-asarone in the preparation of drugs for treating and / or preventing eye diseases, a composition and the use thereof. Background Art
[0002] The optic nerve is composed of the axons of retinal ganglion cells (RGC), which converge at the optic disc, pass through the scleral lamina, run backwards in the eye frame, and pass through the optic canal into the cranial fossa, connecting to the diencephalon through the optic chiasm and optic tract. Since the optic nerve is part of the visual organ formed by the outward protrusion of the midbrain during embryonic development, it belongs to the central nervous system. Its three-layer sheath is covered by the dura mater, arachnoid mater and pia mater, which are also the continuation of the three layers of meninges. The optic nerve is an important part of the visual pathway, transmitting visual information obtained by the retina to the brain. Due to its anatomical characteristics, the optic nerve is easily damaged, including primary damage caused by direct mechanical trauma, axon interruption and shear stress, and secondary damage caused by inflammation, neurotoxic factors and vascular dysfunction. According to statistics, 0.5% to 5% of closed head traumas are accompanied by optic nerve damage, and the affected population is mainly young and middle-aged people. Damage to the optic nerve can cause secondary death of retinal ganglion cells and axonal degeneration, resulting in severe visual dysfunction such as decreased vision, visual field loss, and color vision loss, and ultimately irreversible vision loss. The low regenerative capacity of the remaining surviving retinal ganglion cells after optic nerve damage, the lack of neurotrophic factors, the formation of glial scars, and the inhibitory environment of the myelin sheath further limit the recovery of visual function. Optic nerve damage is a serious disease that causes great inconvenience to patients and is difficult for clinicians to treat, bringing a heavy burden to patients' families and society. Many ophthalmic diseases are closely related to optic nerve damage, such as glaucoma, optic neuritis, traumatic optic nerve damage, and diabetic retinopathy.
[0003] Glaucoma refers to a disease characterized by intermittent or continuous increase in intraocular pressure, with characteristic optic nerve atrophy and visual field loss as common features. Pathological increase in intraocular pressure is its main risk factor. Continuous high intraocular pressure can cause damage to various tissues and visual functions of the eyeball, resulting in decreased vision and reduced visual field. It is a blinding eye disease characterized by progressive visual field loss, leading to irreversible and non-selective death of retinal ganglion cells. Clinically, glaucoma is divided into primary glaucoma, angle-closure glaucoma, open-angle glaucoma, secondary glaucoma and congenital glaucoma. Its treatment strategies include promoting optic nerve repair, ferroptosis, pyroptosis, glutamate excitotoxicity, oxidative stress, etc. However, due to the complexity of the pathogenesis of glaucoma, the current research on these factors and their interactions is still not completely clear, and there is still a huge unmet clinical need for the treatment of glaucoma.
[0004] Optic neuritis (ON) refers to all inflammatory lesions related to the optic nerve, with decreased or lost vision as the main clinical manifestation, with or without eye movement pain, etc., and mostly affects one eye. ON is generally divided into typical ON and atypical ON internationally. Typical ON is an idiopathic inflammatory demyelinating disease, usually associated with multiple sclerosis (MS), mostly unilaterally involved, subacute, and patients experience decreased vision within hours or days of onset. Atypical ON is often associated with autoimmune and infectious diseases, and is divided into neuromyelitis optica spectrum disorder (NMOSD)-related ON, chronic recurrent inflammatory optic neuropathy, and systemic disease-related ON. Currently, the treatment of ON mainly includes hormone therapy, immunosuppression, MS correction therapy plasma exchange, immunoadsorption, etc., as well as Chinese medicine compound treatment, acupuncture, etc. The above therapies have problems such as large adverse reactions and poor treatment compliance, so it is of great significance to develop new drugs for the treatment of ON.
[0005] Diabetic retinopathy (DR) is one of the most common eye complications in diabetic patients. As the global prevalence of diabetes increases, the global prevalence of DR also increases. According to the International Diabetes Federation, the number of patients with type I and type II diabetes worldwide will reach 700 million in 2045, of which the prevalence of vision-threatening DR is about 6% of diabetic patients. If DR is not treated in time, it can lead to retinal edema, hemorrhage, and neovascularization, which can cause retinal detachment and threaten vision in severe cases. The cause of DR is still unclear at this stage. According to the degree and characteristics of the lesions, DR can usually be divided into two types: nonproliferative and proliferative. Nonproliferative diabetic retinopathy (NPDR) manifests microvascular tumors and microvascular tumor-like lesions, while proliferative diabetic retinopathy (PDR) mainly involves the formation of new blood vessels, which may lead to severe retinal detachment. The main treatments currently include retinal laser photocoagulation, anti-VEGF drugs, corticosteroids, and a combination of multiple drugs.
[0006] Neovascular age-related macular degeneration (nAMD) is characterized by choroidal neovascularization (CNV) or retinal neovascularization in the macular area, which may be accompanied by retinal edema and changes such as retinal exudation, hemorrhage, and scarring. At present, its pathogenesis is still unclear and may be related to multiple factors such as age, environment, genetics, oxidative stress, lipid metabolism, and immune response. Among them, vascular endothelial growth factor (VEGF) has been proven to play an important role in the formation of neovascularization in nAMD. At present, anti-VEGF therapy has become the most important targeted treatment for nAMD patients, but anti-VEGF therapy also brings many challenges and difficulties, such as patients needing multiple intravitreal injections, macular atrophy progression during treatment, fundus fibrous scar formation, and patients' vision returning to baseline level after 5 years of treatment. Some patients even have poor or no response to anti-VEGF treatment. Therefore, it is of great significance to explore various new treatment strategies in order to achieve better efficacy.
[0007] Cataract is caused by damage to the lens capsule due to various reasons, which increases its permeability and loses its barrier function, or causes lens metabolism disorder, causing lens protein denaturation and turbidity. The pathogenesis of cataract is related to oxidative stress, apoptosis, autophagy and epithelial-mesenchymal transition. At present, there is no effective drug therapy for cataract. Early cataract is mostly treated with eye drops, and patients in the middle and late stages are mainly treated with surgery. Therefore, it is of great significance to develop drugs that can treat or delay the progression of cataract.
[0008] Dry eye syndrome (Xerophthalmia), also known as keratoconjunctivitis sicca, is one of the most common ophthalmic diseases caused by low tear gland secretion due to various reasons in the eye and / or the whole body, resulting in abnormal tear film and dryness of the ocular surface epithelium. It is an ocular surface disease caused by various disorders in the natural functions and protective mechanisms of the external eye, resulting in unstable tear film during blinking. Clinically, it is often divided into aqueous tear deficiency (ATD) and lipid tear deficiency (LTD) according to the cause of tear deficiency. The main causes are immune inflammation and apoptosis, and changes in hormone levels. Currently available treatments include artificial tears, immunomodulators, and surgical treatments, but the effects are poor.
[0009] In summary, there is currently a lack of effective preventive and therapeutic drugs for the above-mentioned eye diseases in clinical practice. Summary of the invention
[0010] In order to solve the above problems, the present invention provides the use of asarone in preparing a drug for treating and / or preventing eye diseases and a composition and the use thereof.
[0011] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0012] The present invention provides the use of asarone in preparing medicines for treating and / or preventing eye diseases, wherein the eye diseases include retinal ganglion cell damage diseases and macular degeneration, cataract or dry eye.
[0013] Preferably, the retinal ganglion cell damage disease includes glaucoma, optic neuritis or diabetic retinopathy.
[0014] The present invention also provides a composition, comprising at least one of α-asarone, β-asarone and γ-asarone at an effective concentration, preferably α-asarone, wherein the final concentration of α-asarone is 0.5 to 30 g / L. The structural formula of α-asarone, β-asarone or γ-asarone is as follows:
[0015]
[0016] Preferably, the composition further comprises an oil solvent, an emulsifier, an osmotic pressure regulator, a pH regulator and water.
[0017] Preferably, the oil solvent includes soybean oil, the emulsifier includes egg yolk lecithin, the osmotic pressure regulator includes glycerol, and the pH regulator includes sodium hydroxide.
[0018] Preferably, the composition is in the form of eye drops, oral preparation or injection.
[0019] Preferably, the eye drops use water as solvent and contain the following components in concentrations: 0.5-5 g / L asarone, 4-50 g / L soybean oil, 1-15 g / L egg yolk lecithin, 2-25 g / L glycerol, and 0.001-0.005 g / L sodium hydroxide.
[0020] Preferably, the oral or injection preparation uses water as solvent and contains the following components in concentrations: 4-30 g / L α-asarone, 80-300 g / L soybean oil, 10-20 g / L egg yolk lecithin, 20-30 g / L glycerol, and 0.02-0.1 g / L sodium hydroxide.
[0021] The present invention also provides the use of the composition in preparing a drug for treating and / or preventing eye diseases, wherein the eye diseases include glaucoma, optic neuritis, diabetic retinopathy, macular degeneration, cataract or dry eye.
[0022] By adopting the above technical scheme, the present invention has the following beneficial effects: the asarone composition of the present invention comprises the following ingredients: at least one of α-asarone, β-asarone and γ-asarone, preferably α-asarone, soybean oil, egg yolk lecithin, glycerol, sodium hydroxide, and water. The asarone or asarone composition of the present invention is administered by eye drops, oral administration, and injection, which can effectively reduce intraocular pressure, protect retinal ganglion cells, improve retinal function, reduce vascular leakage caused by neovascular age-related macular degeneration, and reduce the MDA content in retinal tissue of optic neuritis and cataract, reduce retinal cell apoptosis in diabetic retinopathy, and increase the tear secretion of dry eye rats. The present invention provides an effective prevention and treatment basis for α-asarone in the treatment and / or prevention of the above eye diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a statistical chart of intraocular pressure after pre-administration for one week and modeling followed by administration for 1 to 4 weeks in Example 3 (n=10).
[0024] Figure 2 This is a statistical graph of the dark-adapted 3.0 ERG a-wave amplitude in each group that was administered for 1 week in advance and modeled and then administered for 1 to 4 weeks after Example 3 (n=10).
[0025] Figure 3 This is a statistical graph of the dark-adapted 3.0 ERG b-wave amplitude in each group that was administered for 1 week in advance and modeled and then administered for 1 to 4 weeks after Example 3 (n=10).
[0026] Figure 4 This is a statistical graph of the changes in the amplitude of visual evoked potential (F-VEP) in each group after pre-administration for one week and modeling and then administration for two weeks in Example 4 (n=8).
[0027] Figure 5 The retinal thickness diagrams of the groups treated with the drug for 1 week in advance and 2 weeks after modeling in Example 4 (n=10) are shown. Compared with the model control group, ***P<0.001.
[0028] Figure 6 This is a statistical graph of dark-adapted ERG a-wave amplitudes in each group that was administered for one week in advance and then administered for two weeks after modeling in Example 5 (n=10).
[0029] Figure 7 The statistical graphs of dark-adapted ERG b-wave amplitudes of each group after pre-administration for one week and modeling and then administration for two weeks in Example 5 (n=10).
[0030] Figure 8 This is a statistical graph of the changes in the amplitude of visual evoked potential (F-VEP) in each group after pre-administration for one week and modeling and then administration for two weeks in Example 5 (n=8).
[0031] Fig. 9 This is the leakage grade score of fundus angiography images of each group in Example 6, which was administered for 3 days in advance and then administered for 7 days after modeling. Compared with the model control group, *P<0.05.
[0032] Fig.10 This is a statistical graph of the maximum central thickness of choroid CNV in each group after 3 days of pre-administration and 7 days of administration after modeling (n=8).
[0033] Fig.11 This is a bar graph showing the effect of α-asarone on glutamate-induced apoptosis of R28 cells in Example 7 (n=6).
[0034] Fig.12 This is a statistical diagram of the retinal MDA content of each group of rats in Example 8 (n=10).
[0035] Fig.13 This is a statistical diagram of the number of retinal apoptotic cells in each group in Example 9 (n=10).
[0036] Fig.14 This is a statistical graph of the retinal MDA content in each group of rats in Example 10.
[0037] Fig.15 This is a statistical chart of tear secretion in each group of rats in Example 11. DETAILED DESCRIPTION
[0038] The present invention provides the use of asarone in preparing a drug for treating and / or preventing eye diseases, wherein the eye diseases include retinal ganglion cell damage diseases and macular degeneration, cataract or dry eye. The retinal ganglion cell damage diseases include glaucoma, optic neuritis or diabetic retinopathy.
[0039] The present invention also provides a composition, comprising at least one of α-asarone, β-asarone and γ-asarone at an effective concentration, preferably α-asarone, and the final concentration of the α-asarone is 0.5 to 30 g / L, more preferably 10 to 20 g / L, and more preferably 15 g / L. The composition also includes an oil solvent, an emulsifier, an osmotic pressure regulator, a pH regulator and water. In the present invention, the oil solvent includes soybean oil, the emulsifier includes egg yolk lecithin, the osmotic pressure regulator includes glycerol, and the pH regulator includes sodium hydroxide.
[0040] The dosage form of the composition of the present invention is eye drops, oral preparation or injection.
[0041] In the present invention, the eye drops use water as solvent and contain the following components in concentrations: 0.5-5 g / L α-asarone, 4-100 g / L soybean oil, 1-15 g / L egg yolk lecithin, 2-25 g / L glycerol, and 0.001-0.005 g / L sodium hydroxide.
[0042] The concentration of α-asarone in the eye drops is 0.5 to 5 g / L, more preferably 1 to 4 g / L, and more preferably 2 g / L;
[0043] The concentration of soybean oil is 4 to 100 g / L, more preferably 20 to 80 g / L, and even more preferably 50 g / L;
[0044] The concentration of egg yolk lecithin is 1 to 15 g / L, more preferably 5 to 10 g / L, and more preferably 8 g / L;
[0045] The concentration of glycerol is 2 to 25 g / L, more preferably 10 to 20 g / L, and more preferably 15 g / L;
[0046] The concentration of sodium hydroxide is 0.001 to 0.005 g / L, more preferably 0.002 to 0.004 g / L, and even more preferably 0.003 g / L.
[0047] In the present invention, the oral preparation or injection uses water as solvent and contains the following components in concentrations: 4-30 g / L α-asarone, 80-300 g / L soybean oil, 10-20 g / L egg yolk lecithin, 20-30 g / L glycerol, and 0.02-0.1 g / L sodium hydroxide.
[0048] The concentration of α-asarone in the oral preparation or injection is 4 to 30 g / L, more preferably 10 to 20 g / L, and more preferably 15 g / L;
[0049] The concentration of soybean oil is 80 to 300 g / L, more preferably 100 to 200 g / L, and more preferably 150 g / L;
[0050] The concentration of egg yolk lecithin is 10 to 20 g / L, more preferably 12 to 18 g / L, and more preferably 15 g / L;
[0051] The concentration of glycerol is 20 to 30 g / L, more preferably 22 to 28 g / L, and more preferably 25 g / L;
[0052] The concentration of sodium hydroxide is 0.02 to 0.1 g / L, preferably 0.04 to 0.08 g / L, and more preferably 0.06 g / L.
[0053] The soybean oil, egg yolk lecithin and glycerol described in the present invention are preferably soybean oil for injection, egg yolk lecithin for injection and glycerol for injection.
[0054] If necessary, the composition of the present invention may also be added with pharmaceutically acceptable antibacterial agents, such as acids, alcohols, quaternary ammonium salts, p-hydroxybenzoic acid esters, benzoic acid, sorbic acid, etc.
[0055] The present invention also provides the use of the composition in preparing a drug for treating and / or preventing eye diseases, wherein the eye diseases include glaucoma, optic neuritis, diabetic retinopathy, macular degeneration, cataract or dry eye.
[0056] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0057] The high-pressure homogenizer used in the embodiment of the present invention is a Duoning Bio-Experimental High-Pressure Nano-Homogenizer, model: AH-NANO-TKE061; SD rats and C57BL / 6 mice were purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0058] Example 1 Preparation of α-asarone oral emulsion / α-asarone emulsion injection
[0059] 1. Preparation process
[0060] Table 1 Raw materials and dosage
[0061] materials effect Prescription amount α-Asarone Main drug 0.5kg Soybean Oil for Injection Solvent, carrier 5.0kg Egg yolk lecithin for injection Emulsifier 0.6kg Glycerin for injection Isotonicity Agents 1.125kg Sodium hydroxide pH Adjusters 1.25g Water for injection Solvents 50L
[0062] 1) Pour soybean oil for injection into an oil tank, start the stirrer and begin heating, then add α-asarone and egg yolk lecithin for injection at 70°C, maintain the oil temperature at 70°C, stir at 3000rpm / min to evenly disperse the lecithin in the oil phase, and stir for 20min to completely dissolve the lecithin.
[0063] 2) Add 45L of water for injection into the preparation tank. Then add the weighed glycerol for injection and sodium hydroxide, start the agitator to stir evenly, and enter the water phase tank through a filter (0.22μm, 5-inch pp, Hangzhou Kebete Instrument Co., Ltd.). Control the water phase temperature to 70℃. Fill with nitrogen for protection and adjust the water phase to a sufficient amount.
[0064] 3) Under the condition of stirring speed of 3000 rpm / min, the oil phase is slowly pressed into the water phase with nitrogen, the flow rate is controlled, and the transfer is completed in about 5 minutes to obtain colostrum.
[0065] 4) The colostrum is homogenized twice by a high-pressure homogenizer, each time for 30 minutes, and the temperature of the liquid should be controlled at 60°C. The homogenization conditions for each time are as follows:
[0066] Table 2 Pressure and temperature of high pressure homogenizer
[0067] Homogenization times Homogenizing pressure (bar) Temperature control after homogenization Homogenization time 1 700bar±50 60℃ 30min 2 700bar±50 60℃ 30min
[0068] After homogenization begins, adjust the homogenization pressure and the liquid medicine can be transferred to the next storage tank only after reaching the specified pressure.
[0069] 2. Filling, sterilization and storage
[0070] 1) After homogenization, cool the liquid medicine to 30℃ and transfer it to a static tank for storage, waiting for filling. The liquid medicine is filtered by nitrogen pressure and sent to the filling;
[0071] 2) Filling and sealing
[0072] The prepared emulsion was poured into the washed ampoule by a filling machine through a 5 μm PP filter element (20 inches, Hangzhou Kebet Filter Equipment Co., Ltd.), and immediately nitrogen-filled and sealed.
[0073] 3) Sterilization
[0074] Sterilize the product in a rotary sterilizer (121℃×10min, F0 value ≥12).
[0075] 4) Packaging and storage
[0076] The sterilized product is packed into cartons after being inspected by light, thus obtaining α-asarone emulsion injection with a concentration of 10 mg / mL.
[0077] Example 2 Preparation of α-asarone emulsion eye drops
[0078] 1. Preparation process
[0079] Table 3 Raw materials and dosage
[0080] materials effect Prescription amount α-Asarone Main drug 2.0g Soybean Oil for Injection Solvent, carrier 50g Egg yolk lecithin for injection Emulsifier 12g Glycerin for injection Isotonicity Agents 22.5g Sodium hydroxide pH Adjusters 0.025g Water for injection Solvents 1.0L
[0081] The raw materials and dosage of the α-asarone emulsion eye drops in this example are shown in Table 3, and the preparation method is the same as that in Example 1.
[0082] 2. Sterilization, filling and storage
[0083] 1) Sterilization
[0084] A non-terminal sterilization process is used to sterilize the polyester (PET) packaging material using a vaporized hydrogen peroxide sterilizer. At the same time, the filling process of the preparation of α-asarone emulsion eye drops must be operated under corresponding clean environment conditions.
[0085] 2) Filling
[0086] After homogenization, the liquid medicine is cooled to 30℃ and transferred to a static tank for storage, waiting for filling. The liquid medicine is filtered by nitrogen pressure and sent to the filling machine; the prepared emulsion is filtered through a 5μm PP filter element (20 inches, Hangzhou Kebet Filter Equipment Co., Ltd.) and filled into a pre-cleaned, dried and sterilized polyester (PET) packaging container by the filling machine.
[0087] 3) Packaging and storage
[0088] The product was packed into cartons after being inspected by light, thus obtaining α-asarone emulsion eye drops with a concentration of 2.0 mg / mL.
[0089] Comparative Example 1
[0090] Different from Example 2, the comparative example 1 prepared an emulsion eye drop without α-asarone. Except for the absence of α-asarone, other reagents and preparation methods were the same as those of Example 2. The following experiments are referred to as "blank emulsion eye drops".
[0091] Experimental Example 1 Protective effect of α-asarone emulsion eye drops on the rat model of chronic ocular hypertension glaucoma induced by magnetic microspheres
[0092] 1. Reagents and Materials
[0093] 30 6-8 week old SD rats, SPF grade, male, weighing 180-220 g; magnetic polystyrene microspheres (PS for short); α-asarone emulsion eye drops (prepared according to the method in Example 2, with a concentration of 2.0 mg / mL).
[0094] 2. Animal grouping and drug administration
[0095] The experimental rats were randomly divided into three groups, namely, normal control group (Control group, n=10), model control group (PS group, n=10), and α-asarone emulsion eye drops group (α-asarone group, n=10).
[0096] One week in advance, rats in the α-asarone emulsion eye drops group were given 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) by eye drops every 3.5 hours from 8:30 to 18:00 every day; on the 8th day, 10 μL of 5 μm diameter, 50 mg / mL magnetic polystyrene microspheres were injected into the right anterior chamber of the eye of the rats in the model control group and the α-asarone group under a surgical microscope to induce unilateral intraocular pressure elevation, and the same amount of sterile saline was injected into the same part of the eye of the normal control group. After the model was established, rats in the α-asarone group were given 20 μL of α-asarone emulsion eye drops every 3.5 hours from 8:30 to 18:00 every day for 4 weeks. At the same time, the PS group was given an equal volume of blank emulsion eye drops without α-asarone by eye drops.
[0097] 3. Evaluation methods and results
[0098] The intraocular pressure of rats was measured before modeling and 1, 2, 3, and 4 weeks after modeling. Figure 1 , as shown in Table 4; at the 1st, 2nd, 3rd, and 4th week, the ERG waveform was detected using the dark adaptation 3.0 method to observe the changes. Figure 2-3 , as shown in Tables 5 and 6. The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistics; post hoc comparisons used LSD test (homogeneous variance) or Dunnett-t test (uneven variance); P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPad Prism 9.3.0. The specific results are as follows:
[0099] Table 4 Comparison of intraocular pressure of rats in each group before modeling and after drug administration (mmHg)(n=10)
[0100] Control Group PS Group α-asarone group Before modeling 12.97±1.89 13.80±0.36 13.24±1.25 Week 1 13.63±4.37**** 27.31±3.12 24.28±1.63* Week 2 11.82±2.41**** 25.62±1.70 20.50±2.76**** Week 3 12.26±1.97**** 26.80±2.23 17.26±1.04**** Week 4 13.54±2.20**** 28.10±3.14 16.74±2.05****
[0101] Table 5 Changes in the amplitude of the ERG a wave during dark adaptation (μV)(n=10)
[0102] Control Group PS Group α-asarone group Week 1 83.21±22.40** 56.25±14.62 60.25±18.53 Week 2 88.74±18.09*** 48.39±14.04 73.68±25.56** Week 3 96.85±29.58*** 55.75±23.52 89.33±12.03** Week 4 84.37±22.30** 53.45±19.53 78.18±15.95**
[0103] Table 6 Changes in the amplitude of the 3.0 ERGb wave in dark adaptation (μV)(n=10)
[0104] Control Group PS Group α-asarone group Week 1 207.58±24.41**** 92.01±23.79 168.17±32.34**** Week 2 226.90±29.32**** 123.00±46.78 197.54±37.26*** Week 3 239.28±47.07**** 102.33±21.72 180.09±49.01*** Week 4 201.74±32.08**** 122.09±36.72 193.08±22.67****
[0105] Note: Compared with the PS group, *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.
[0106] The a wave is generated by the outer retinal cells (mainly rods and cones), which reflects the function of the photoreceptors; the b wave is generated by the inner retinal cells (mainly bipolar cells and Muller cells), which reflects the function of the middle layer of the retina.
[0107] From Tables 4 to 6 and Figures 1 to 3 It can be seen that after 4 weeks of continuous administration, the intraocular pressure of rats slowly decreased; under dark-adapted flash stimulation, the amplitude size at each time point was ranked as follows: Control group>α-asarone group>PS group, and there were significant or extremely significant differences between the α-asarone group and the PS group (P<0.001 or P<0.0001), indicating that preventive administration of α-asarone can effectively reduce intraocular pressure, increase the amplitude of flash stimulation, and improve retinal function in mice with chronic high intraocular pressure.
[0108] The inventors have found through experimental studies that the pharmacodynamic performance of α-asarone emulsion eye drops is basically consistent with the intraperitoneal injection (ip) dose of 30 mg / kg of α-asarone emulsion injection and the intragastric administration (ig) dose of 60 mg / kg of α-asarone oral emulsion; in addition, α-asarone and β-asarone or γ-asarone have the same or similar efficacy when used for the treatment and / or prevention of eye diseases. To simplify the description, the following experiments only show the pharmacodynamic results of α-asarone emulsion eye drops.
[0109] Experimental Example 2 Protective effect of α-asarone emulsion eye drops on N-methyl-D-aspartate (NMDA)-induced retinal ganglion cell damage
[0110] 1. Reagents and Materials
[0111] A total of 28 6-8 week old SD rats, SPF grade, male, weighing 180-220 g; NMDA; α-asarone emulsion eye drops (prepared according to the method in Example 2, with a concentration of 2.0 mg / mL).
[0112] 2. Animal grouping and drug administration
[0113] The experimental rats were randomly divided into three groups, namely, normal control group (Control group, n=10), model control group (NMDA group, n=10), and α-asarone emulsion eye drops group (α-asarone group, n=10).
[0114] One week in advance, rats in the α-asarone emulsion eye drops group were given 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) by eye drops every 3.5 hours from 8:30 to 18:00 every day; on the 8th day, 3 μL of NMDA (50 mM) solution was slowly injected into the vitreous cavity of the right eye of the model control group and the α-asarone group under an optical microscope with a 33G needle to induce neuroexcitotoxicity, and the eyes of the normal control group were injected with an equal amount of sterile saline. After the model was established, rats in the α-asarone group were given 20 μL of α-asarone emulsion eye drops every 3.5 hours from 8:30 to 18:00 every day for 2 weeks. At the same time, the NMDA group was given an equal volume of blank emulsion eye drops without α-asarone by eye drops.
[0115] 3. Evaluation methods and results
[0116] The amplitude changes of flash visual evoked potential (F-VEP) of rats in each group were detected in the second week after modeling. Figure 4 , as shown in Table 7; In the second week, the eyeballs of rats in each group were removed to make paraffin sections, and HE staining was performed. The retinal thickness of rats in each group was counted. The results are shown in Figure 5 , as shown in Table 8. The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistics; post hoc comparisons used LSD test (homogeneous variance) or Dunnett-t test (unequal variance); P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPad Prism 9.3.0. The specific results are as follows:
[0117] Table 7 Changes in the amplitude of visual evoked potential F-VEP (n=10)
[0118] Control Group NMDA group α-asarone group N1-P1 amplitude (μV) 45.29±4.31**** 17.14±9.11 29.74±5.72***
[0119] Table 8 Changes in retinal thickness of rats in each group (n=10)
[0120] Control Group NMDA group α-asarone group Retinal thickness (μm) 208.71±10.85**** 160.11±24.83 194.82±17.49***
[0121] Note: Compared with the NMDA group, ***P<0.001; ****P<0.0001.
[0122] From Tables 7 to 8 and Figures 4-5It can be seen that after 2 weeks of continuous administration, the thickness of the rat retina increased and some electrophysiological functions were restored. There were significant or extremely significant differences between the drug-treated group and the model group (P<0.001 or P<0.0001), indicating that preventive administration of α-asarone has a protective effect on RGC death, retinal morphology and optic nerve function damage induced by intravitreal injection of 50mM NMDA in rats.
[0123] Experimental Example 3 The therapeutic effect of α-asarone emulsion eye drops on traumatic optic neuropathy in rats
[0124] 1. Reagents and Materials
[0125] 30 6-8 week old SD rats, SPF grade, male, weighing 180-220 g; α-asarone emulsion eye drops (prepared according to the method in Example 2, with a concentration of 2.0 mg / mL).
[0126] 2. Animal grouping and drug administration
[0127] The experimental rats were randomly divided into three groups, namely, a normal control group (Control group, n=10), an optic nerve crush model control group (ONC group, n=10), and an α-asarone emulsion eye drops group (α-asarone group, n=10).
[0128] One week in advance, rats in the α-asarone emulsion eye drops group were given 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) by eye drops every 3.5 hours from 8:30 to 18:00 every day; on the 8th day, the model control group and the α-asarone emulsion eye drops group underwent optic nerve crush surgery, and the normal control group was not treated. After the model was established, rats in the α-asarone emulsion group were given 20 μL of α-asarone emulsion eye drops every 3.5 hours from 8:30 to 18:00 every day for 2 weeks. At the same time, the ONC group was given an equal volume of blank emulsion eye drops without α-asarone by eye drops.
[0129] 3. Evaluation methods and results
[0130] The ERG waveform was detected in the second week after modeling. Figure 6-7 , as shown in Tables 9 and 10; at the same time, the amplitude changes of flash visual evoked potential (F-VEP) of rats in each group were measured in the second week. Figure 8, as shown in Table 11. The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistics; post hoc comparisons used LSD test (homogeneous variance) or Dunnett-t test (unequal variance); P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPadPrism 9.3.0. The specific results are as follows:
[0131] Table 9 Changes in the amplitude of ERG a wave in dark adaptation (μV)(n=10)
[0132]
[0133] Table 10 Changes in the amplitude of ERG b wave in dark adaptation (μV)(n=10)
[0134]
[0135] Table 11 Changes in the amplitude of visual evoked potential F-VEP (n=10)
[0136] Control Group ONC Group α-asarone group N1-P1 amplitude (μV) 36.19±4.87**** 12.56±2.40 25.56±6.61****
[0137] Note: Compared with the ONC group, *P<0.05; **P<0.01; ****P<0.0001.
[0138] From Tables 9 to 11 and Fig.13 It can be seen that after stimulation with different light intensities, the amplitudes measured after 1 week of pre-administration and 2 weeks of administration after modeling were ranked as follows: Control group>α-asarone group>ONC group, indicating that preventive eye drops of α-asarone can effectively increase the amplitude of each flash stimulus and alleviate optic nerve damage in rats caused by external pressure.
[0139] Experimental Example 4 Protective effect of α-asarone emulsion eye drops on laser-induced choroidal neovascularization in mice
[0140] 1. Reagents and Materials
[0141] 30 C57BL / 6 mice aged 7 to 8 weeks, SPF grade, male, weighing 19 to 21 g; α-asarone oral emulsion / α-asarone emulsion eye drops (prepared according to the method in Example 1, with a concentration of 10 mg / mL).
[0142] 2. Animal grouping and drug administration
[0143] The experimental mice were randomly divided into two groups, namely, a normal control group (Control group, n=6), a choroidal neovascularization (CNV group, n=12), and an α-asarone emulsion eye drops group (α-asarone group, n=12).
[0144] Three days in advance, rats in the α-asarone emulsion eye drops group were given 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) by eye drops every 3.5 hours from 8:30 to 18:00 every day; on the 4th day, the CNV group and the α-asarone group were subjected to 532 nm laser photocoagulation modeling, and the normal control group was not treated. After the modeling was completed, rats in the α-asarone emulsion group were given 20 μL of α-asarone emulsion eye drops every 3.5 hours from 8:30 to 18:00 every day, and the eye drops were continued for 2 weeks. At the same time, the CNV group was given an equal volume of blank emulsion eye drops without α-asarone by eye drops.
[0145] 3. Evaluation methods and results
[0146] On the 7th day after laser photocoagulation, the mice in each group were examined by fundus fluorescein angiography (FFA). Fig. 9 , as shown in Table 12; at the same time, the eyeballs of mice in each group were removed to make paraffin sections, HE staining was performed, and the maximum central thickness of CNV in each group of mice was counted. Fig.10 , as shown in Table 13. The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistical analysis; LSD test (homogeneous variance) or Dunnett-t test (unequal variance) was used for post hoc comparison; P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPadPrism 9.3.0.
[0147] Table 12 Fundus angiography leakage grade scores of mice in each group (n=12)
[0148] CNV Group α-asarone group Number of Level 3 (percentage) 21 / 43(49%) 9 / 40(23%) Average leakage level 2.11±1.00 1.65±0.92*
[0149] Table 13 Changes in the maximum central thickness of CNV in each group of mice (μm)(n=12)
[0150]
[0151]
[0152] Note: Compared with the CNV group, *P<0.05; **P<0.01; ****P<0.0001.
[0153] From Tables 12 to 13 and Figures 9-10 It can be seen that pre-administration for 3 days and then continuous administration for 7 days can reduce the leakage of fluorescein in laser spots of laser-induced mice and reduce the formation of CNV. The results of in vitro eyeball HE staining and fundus fluorescence angiography were basically consistent, and there were significant differences between the drug-treated group and the model group (P<0.05). This shows that preventive administration of α-asarone can effectively inhibit the formation of laser-induced CNV in mice and has a certain therapeutic effect on laser-induced CNV in mice.
[0154] Experimental Example 5 Protective effect of α-asarone on glutamate-damaged R28 cells
[0155] 1. Reagents and Materials
[0156] Rat retinal progenitor cell line (R28) was from Wuhan Pronocell Life Science Co., Ltd.; L-glutamate (McLean, L810369); CCK-8 (Biosharp, BS350C); DMEM / F12 medium (containing double antibody) (Keygen, KGM12500-500); fetal bovine serum (ZETA, 120214018-4S); PBS (Keygen, KGB5001); DMSO (Solebio, D8371).
[0157] 2. Experimental Procedure
[0158] 1) Glutamate modeling concentration screening: R28 cells were cultured with different concentrations of glutamate for 24 h, and it was found that the cell viability was about 60% in the presence of 10 mM glutamate. Therefore, 10 mM glutamate was selected for modeling.
[0159] 2) α-asarone drug efficacy screening: R28 cells in the logarithmic growth phase cultured in complete medium were cultured at 1×10 4The cells were inoculated into a 96-well plate at a density of 100 μL / well, and the edge wells were filled with sterile PBS. The cells were cultured at 37°C and 5% CO2 for 24 hours until the cells were completely attached to the wall. The supernatant was discarded, and 50 μL of α-asarone solution with a final concentration of 0.5 μM, 1 μM, and 2 μM was added, and the cells were cultured at 37°C and 5% CO2 for 2 hours. Then, a glutamate solution diluted with serum-free medium at a final concentration of 10 mM was added to each of the above-mentioned drug-treated groups, 50 μL per well, and the culture was continued at 37°C and 5% CO2 for 24 hours. The control group only added the same volume of serum-free medium; the model group added 50 μL of serum-free medium and 50 μL of glutamate solution diluted with serum-free medium at a final concentration of 10 mM in sequence; the rest of the operations of the control group and the model group were the same as those of the drug-treated group. Then, 110 μL of 10% CCK-8 solution was added to each well and cultured for 2 h at 37° C. and 5% CO 2 . The OD value at 450 nm was detected by an enzyme-labeled instrument, and the R28 cell viability was calculated according to the following formula.
[0160] Cell viability = (average absorbance value of the experimental group - average absorbance value of the zero-adjusted well) / (average absorbance value of the normal control group - average absorbance value of the zero-adjusted well).
[0161] Fig.11 The results of cell efficacy were obtained by pre-administering α-asarone at a final concentration of 0.5, 1, and 2 μM for 2 hours, and then administering glutamate at a final concentration of 10 mM for 24 hours. As shown in the figure, compared with the Glu group, the absorbance of the preventive administration groups at different concentrations increased and had significant differences, and the cell viability was the highest at 2 μM. This shows that preventive administration of α-asarone has a protective effect on R28 cells.
[0162] Experimental Example 6 Protective effect of α-asarone emulsion eye drops on optic neuritis rat model induced by inflammation
[0163] 1. Reagents and Materials
[0164] A total of 34 6-8 week old SD rats, SPF grade, female, weighing 180-220 g; guinea pig spinal cord homogenate; Complete Freund Adjuvant (CFA); pertussis vaccine; α-asarone emulsion eye drops (prepared according to Example 2, concentration of 2 mg / mL)
[0165] 2. Animal grouping and drug administration
[0166] SD rats were adaptively raised for one week, and 10 SD rats were randomly selected as the normal control group (Control group, n=10). The remaining 24 SD rats were subcutaneously injected with guinea pig spinal cord homogenate plus complete Freund Adjuvant (CFA) as antigen into the foot pads of the rats, and pertussis vaccine was subcutaneously injected into the hind limbs at the same time to establish the experimental autoimmune encephalomyelitis (EAE) model in rats; the Control group was injected with an equal amount of normal saline in the same way. Twelve rats with successfully established model were randomly selected as the α-asarone group, and 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) were administered by eye drops every 3.5 h from 8:30 to 18:00 every day for 3 consecutive weeks; the remaining 12 rats were used as the EAE group, and an equal volume of blank emulsion without α-asarone was administered by eye drops every 3.5 h from 8:30 to 18:00 every day for 3 consecutive weeks.
[0167] 3. Evaluation methods and results
[0168] After 3 weeks of administration, the rat retinas were removed to detect the MDA content. The results are shown in Table 14. Fig.12 The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistical analysis; post hoc comparisons were performed using LSD test (homogeneous variance) or Dunnett-t test (uneven variance); P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPadPrism 9.3.0.
[0169] Table 14 Retinal MDA content of rats in each group (n=10)
[0170]
[0171] Note: Compared with the EAE group, **** P<0.0001.
[0172] The results are shown in Table 14. Fig.12 As shown, the MDA content test results showed that the MDA content in the EAE group was significantly higher than that in the Control group and the α-asarone group, and the difference was significant; while there was no significant difference between the Control group and the α-asarone group, indicating that the EAE group had severe oxidative damage, while the α-asarone group had no obvious damage. Therefore, α-asarone can alleviate the damage to the retina caused by inflammation.
[0173] Experimental Example 7 Protective effect of α-asarone emulsion eye drops on streptozotocin-induced diabetic retinopathy rat model
[0174] 1. Reagents and Materials
[0175] A total of 34 6-8 week old SD rats, SPF grade, male, weighing 180-220 g; streptozotocin (STZ); α-asarone emulsion eye drops (prepared in Example 2, with a concentration of 2 mg / mL).
[0176] 2. Animal grouping and drug administration
[0177] SD rats were adaptively raised for one week, and 10 SD rats were randomly selected as the normal control group (Control group, n=10). The remaining 24 SD rats were given STZ solution (60 mg / kg) by intraperitoneal injection (ip). The model was considered successful when the blood glucose value was randomly measured 3 times 72 hours after STZ injection and was ≥16.7 mmol / L; the Control group was injected with an equal amount of normal saline in the same way.
[0178] Twelve rats with successful modeling were randomly selected as the α-asarone group, and 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) were administered by eye drops every 3.5 hours from 8:30 to 18:00 every day for 12 consecutive weeks; the remaining 12 rats were used as the STZ group, and an equal volume of blank emulsion eye drops without α-asarone were administered by eye drops every 3.5 hours from 8:30 to 18:00 every day for 12 consecutive weeks.
[0179] 3. Evaluation methods and results
[0180] After 12 weeks of administration, the rat eyeballs were removed and TUNEL staining was performed to observe the apoptosis of retinal cells. The results are shown in Table 15. Fig.13 The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistical analysis; post hoc comparisons were performed using LSD test (homogeneous variance) or Dunnett-t test (uneven variance); P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPad Prism 9.3.0.
[0181] Table 15 Number of retinal apoptotic cells (n=10)
[0182] Control Group STZ group α-asarone group Number of apoptotic cells 3±1*** 114±38 7±1***
[0183] Note: ***P<0.001 compared with the STZ group.
[0184] The results are shown in Table 15. Fig.13 As shown, the TUNEL staining results showed that the number of apoptotic cells in the STZ group was significantly higher than that in the α-asarone group and the Control group, and the difference was significant; while there was no significant difference between the Control group and the α-asarone group, indicating that the STZ group suffered severe damage due to hyperglycemia, while the α-asarone group had no obvious damage. Therefore, α-asarone can alleviate the damage to retinal cells caused by STZ-induced hyperglycemia.
[0185] Experimental Example 8 Protective effect of α-asarone emulsion eye drops on D-galactose-induced cataract rat model
[0186] 1. Reagents and Materials
[0187] A total of 34 6-8 week old SD rats, SPF grade, male, weighing 180-220 g; D-galactose; α-asarone emulsion eye drops (prepared in Example 2, concentration of 2 mg / mL)
[0188] 2. Animal grouping and drug administration
[0189] SD rats were adaptively raised for one week, and 10 SD rats were randomly selected as the normal control group (Control group, n=10). The remaining 24 SD rats were given D-galactose (200 mg / kg) by subcutaneous injection once a day. After 4 consecutive weeks of injection, the degree of lens opacity of the rats was observed under slit lamp illumination. If the lens was opaque, the model was considered to be successfully established. The Control group was injected with an equal amount of normal saline in the same way.
[0190] Twelve rats with successful modeling were randomly selected as the α-asarone group, and 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) were administered by eye drops every 3.5 h from 8:30 to 18:00 every day for 4 consecutive weeks; the remaining 12 rats were used as the D-galactose group (Veh group), and an equal volume of blank emulsion eye drops without α-asarone were administered by eye drops every 3.5 h from 8:30 to 18:00 every day for 12 consecutive weeks.
[0191] 3. Evaluation methods and results
[0192] After 3 weeks of administration, the rat retinas were removed to detect the MDA content. The results are shown in Table 16. Fig.14The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistical analysis; post hoc comparisons were performed using LSD test (homogeneous variance) or Dunnett-t test (uneven variance); P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPadPrism 9.3.0.
[0193] Table 16 Omentum MDA content in each group of rats (n=10)
[0194]
[0195] Note: Compared with the Veh group, ****P<0.0001.
[0196] The results are shown in Table 16. Fig.14 As shown, the MDA results showed that the MDA content in the Veh group was significantly higher than that in the Control group and the α-asarone group, and the difference was significant; while there was no significant difference between the Control group and the α-asarone group, indicating that the Veh group suffered severe oxidative damage due to hyperglycemia, while the α-asarone group had no obvious damage, indicating that α-asarone can alleviate the oxidative damage to the retina induced by D-galactose.
[0197] Experimental Example 9 Protective effect of α-asarone emulsion eye drops on scopolamine hydrobromide-induced dry eye rat model
[0198] 1. Reagents and Materials
[0199] 34 6-8 week old SD rats, SPF grade, female, weighing 180-220 g; scopolamine hydrobromide (SCOP); α-asarone emulsion eye drops (prepared according to the method in Example 2, with a concentration of 2.0 mg / mL).
[0200] 2. Animal grouping and drug administration
[0201] SD rats were adaptively raised for one week, and 10 SD rats were randomly selected as a normal control group (Control group, n=10). The remaining 24 SD rats were given SCOP (12.5 mg / kg) by subcutaneous injection, 3 hours / time (9:00, 12:00, 15:00, 18:00).
[0202] Twelve rats were randomly selected as the α-asarone group after modeling, and 20 μL of α-asarone emulsion eye drops (2.0 mg / mL) were administered to the rats in the α-asarone group by eye drops every 3.5 h from 8:30 to 18:00 every day for 1 week; the remaining 12 rats were used as the D-galactose group (Veh group), and an equal volume of blank emulsion eye drops without α-asarone were administered to the rats in the α-asarone group by eye drops every 3.5 h from 8:30 to 18:00 every day for 1 week.
[0203] 3. Evaluation methods and results
[0204] The tear secretion of rats in each group was detected on the 7th day after modeling. The results are shown in Table 17. Fig.15 The data results are presented in the form of mean ± standard deviation. After the normality test and variance homogeneity test of the experimental data, one-way ANOVA was used for statistical analysis; post hoc comparisons were performed using LSD test (homogeneous variance) or Dunnett-t test (uneven variance); P < 0.05 was considered to be significantly different. All data were processed and analyzed using IBM SPSS Statistics 27, and all statistical graphs were drawn using GraphPadPrism 9.3.0.
[0205] Table 17 Tear secretion of rats in each group (n=10)
[0206] Detection Control Group SCOP Group α-asarone group Tear secretion volume / mm 11.45±1.71**** 5.98±0.97 7.50±1.70*
[0207] Note: Compared with the SCOP group, *P<0.05; ****P<0.0001.
[0208] The results are shown in Table 17. Fig.15 As shown in the results, the tear secretion of rats in each group was detected, which showed that the tear secretion of the SCOP group was significantly less than that of the Control group and the α-asarone group, and the difference was significant, indicating that the tear secretion caused by the SCOP group was significantly reduced, leading to the occurrence of dry eye, while the α-asarone group was able to alleviate the tear reduction induced by SCOP and play a role in protecting the ocular surface.
[0209] It can be seen from the above examples that the α-asarone and the composition thereof of the present invention can effectively treat and / or prevent diseases related to retinal ganglion cell damage (such as glaucoma, optic neuritis, diabetic retinopathy), neovascular age-related macular degeneration, cataracts, and dry eye eye diseases.
[0210] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of asarone in the preparation of drugs for treating and / or preventing eye diseases, wherein the eye diseases include retinal ganglion cell damage diseases and macular degeneration, cataracts or dry eyes; the asarone includes α-asarone, β-asarone or γ-asarone.
2. The use according to claim 1, characterized in that: The retinal ganglion cell damage disease includes glaucoma, optic neuritis or diabetic retinopathy.
3. A composition, characterized in that The invention comprises asarone of effective concentration, wherein the asarone comprises at least one of α-asarone, β-asarone and γ-asarone, and the final concentration of the asarone is 0.5-30 g / L.
4. The composition according to claim 3, characterized in that In the composition, α-asarone is the only effective active ingredient.
5. The composition according to claim 4, characterized in that The composition further comprises an oil solvent, an emulsifier, an osmotic pressure regulator, a pH regulator and water.
6. The composition according to claim 5, characterized in that The oil solvent includes soybean oil, the emulsifier includes egg yolk lecithin, the osmotic pressure regulator includes glycerol, and the pH regulator includes sodium hydroxide.
7. The composition according to claim 6, characterized in that The dosage form of the composition is eye drops, oral preparations or injections.
8. The composition according to claim 7, characterized in that The eye drops use water as solvent and contain the following components in concentrations: 0.5-5 g / L α-asarone, 4-50 g / L soybean oil, 1-15 g / L egg yolk lecithin, 2-25 g / L glycerol, and 0.001-0.005 g / L sodium hydroxide.
9. The composition according to claim 8, characterized in that The oral preparation or injection uses water as solvent and contains the following components in concentrations: 4-30 g / L of α-asarone, 80-300 g / L of soybean oil, 10-20 g / L of egg yolk lecithin, 20-30 g / L of glycerol, and 0.02-0.1 g / L of sodium hydroxide.
10. Use of the composition according to any one of claims 3 to 9 in the preparation of a drug for treating and / or preventing eye diseases, wherein the eye diseases include glaucoma, optic neuritis, diabetic retinopathy, macular degeneration, cataract or dry eye.
Citation Information
Patent Citations
Application of alpha-asarone in preparation of medicine for treating cerebral arterial thrombosis
CN114129550A
Application of alpha-asarone or alpha-asarone composition in preparation of medicine for treating and / or preventing macular degeneration
CN118717734A
Analogs of pridopidine, their preparation and use
US20220023280A1
Use of α-asarone in preparation of drug for prevention or treatment of cerebral ischemic stroke
WO2022048197A1
Cited By
Application of asarone in preparation of drug for treating and / or preventing ocular diseases, and composition and application thereof
WO2025256439A1
